Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.
BörsenkürzelANIK
Name des UnternehmensAnika Therapeutics Inc
IPO-datumMay 16, 1985
CEODr. Cheryl Renee Blanchard, Ph.D.
Anzahl der mitarbeiter288
WertpapierartOrdinary Share
GeschäftsjahresendeMay 16
Addresse32 Wiggins Ave
StadtBEDFORD
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl01730-2315
Telefon17814579000
Websitehttps://anika.com/
BörsenkürzelANIK
IPO-datumMay 16, 1985
CEODr. Cheryl Renee Blanchard, Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten